Macaulay Amechi Chukwukadibia Onuigbo
1,2*1 The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA
2 College of Business, University of Wisconsin MBA Consortium, Eau Claire, WI, USA
Implication for health policy/practice/research/medical education:
Given the comparable efficacy of the modified-‘modified Ponticelli’ regimens using lower doses
of cyclophosphamide and corticosteroids, respectively, and cognizant of the natural history of
primary membranous nephropathy (MN), every effort to mitigate the deleterious adverse effects of
immunosuppression, while still not losing therapeutic efficacy in the management of primary MN,
must continue to be encouraged.
Please cite this paper as: Onuigbo MAC. The use of modified Ponticelli regimens for primary
membranous nephropathy. J Nephropathol. 2019;8(4):e34. DOI: 10.15171/jnp.2019.34.